ATE426410T1 - Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18 - Google Patents

Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18

Info

Publication number
ATE426410T1
ATE426410T1 AT05789011T AT05789011T ATE426410T1 AT E426410 T1 ATE426410 T1 AT E426410T1 AT 05789011 T AT05789011 T AT 05789011T AT 05789011 T AT05789011 T AT 05789011T AT E426410 T1 ATE426410 T1 AT E426410T1
Authority
AT
Austria
Prior art keywords
human
treatment
oral
administration
intestinal mucositis
Prior art date
Application number
AT05789011T
Other languages
English (en)
Inventor
Judithann Lee
Kimberly Dede
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE426410T1 publication Critical patent/ATE426410T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05789011T 2004-08-20 2005-08-18 Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18 ATE426410T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60301204P 2004-08-20 2004-08-20

Publications (1)

Publication Number Publication Date
ATE426410T1 true ATE426410T1 (de) 2009-04-15

Family

ID=35968167

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05789011T ATE426410T1 (de) 2004-08-20 2005-08-18 Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18
AT09155870T ATE526057T1 (de) 2004-08-20 2005-08-18 Wundheilung durch verabreichung von menschlichem il-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT09155870T ATE526057T1 (de) 2004-08-20 2005-08-18 Wundheilung durch verabreichung von menschlichem il-18

Country Status (23)

Country Link
US (1) US7595039B2 (de)
EP (2) EP1793859B1 (de)
JP (1) JP4912306B2 (de)
KR (1) KR20070050924A (de)
CN (1) CN101039696B (de)
AT (2) ATE426410T1 (de)
AU (1) AU2005277404A1 (de)
BR (1) BRPI0514445A (de)
CA (1) CA2577777A1 (de)
CY (1) CY1108991T1 (de)
DE (1) DE602005013542D1 (de)
DK (1) DK1793859T3 (de)
ES (2) ES2322605T3 (de)
IL (1) IL181286A0 (de)
MX (1) MX2007002134A (de)
NO (1) NO20071238L (de)
NZ (1) NZ552837A (de)
PL (1) PL1793859T3 (de)
PT (1) PT1793859E (de)
RU (1) RU2387455C2 (de)
SI (1) SI1793859T1 (de)
WO (1) WO2006023623A2 (de)
ZA (1) ZA200700524B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
RU2423971C1 (ru) * 2010-06-01 2011-07-20 Закрытое акционерное общество "Биологические исследования и системы" Способ ускорения заживления кожных повреждений, вызванных денервацией и нарушением кровоснабжения
JP6005736B2 (ja) 2011-06-13 2016-10-12 ニューメディシンズ，インコーポレーテッド Ｉｌ−１２を用いる皮膚損傷の軽減
KR102512797B1 (ko) 2013-09-05 2023-03-22 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
SG11201706879UA (en) 2015-03-05 2017-09-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
SG11202001384TA (en) 2017-09-06 2020-03-30 Univ Yale Interleukin-18 variants and methods of use
EP4482531A1 (de) 2022-02-23 2025-01-01 Bright Peak Therapeutics AG Immunantigenspezifische il-18-immunzytokine und verwendungen davon

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
ATE253374T1 (de) * 1998-03-07 2003-11-15 Dae Woong Pharma Topische zusammensetzung enthaltend menschlichen epidermalen wachstumsfaktor
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
MXPA02011969A (es) * 2000-06-02 2004-09-06 Smithkline Beecham Corp Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
CZ20024085A3 (cs) * 2000-06-15 2003-05-14 Smithkline Beecham Corporation Způsob přípravy fyziologicky aktivního IL-18 polypeptidu
EP1405560B1 (de) * 2001-07-12 2011-10-19 Taiho Pharmaceutical Co., Ltd. Il-18 transgenes tier
JP4516844B2 (ja) 2002-09-16 2010-08-04 エイジェニックス インコーポレイテッド 創傷の処置におけるラクトフェリン
EP1572228A4 (de) * 2002-09-19 2009-03-04 Centocor Inc Verfahren zur einleitung der reifung von dendritischen zellen und seine verwendungen
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects

Also Published As

Publication number Publication date
US7595039B2 (en) 2009-09-29
EP1793859B1 (de) 2009-03-25
CN101039696B (zh) 2011-08-17
CY1108991T1 (el) 2014-07-02
EP2161032A3 (de) 2010-07-28
EP2161032B1 (de) 2011-09-28
ES2372728T3 (es) 2012-01-25
KR20070050924A (ko) 2007-05-16
BRPI0514445A (pt) 2008-06-10
CN101039696A (zh) 2007-09-19
ZA200700524B (en) 2008-05-28
WO2006023623A2 (en) 2006-03-02
PT1793859E (pt) 2009-06-04
US20060039892A1 (en) 2006-02-23
WO2006023623A3 (en) 2006-08-24
PL1793859T3 (pl) 2009-08-31
DE602005013542D1 (de) 2009-05-07
DK1793859T3 (da) 2009-06-22
EP1793859A2 (de) 2007-06-13
NZ552837A (en) 2009-09-25
JP4912306B2 (ja) 2012-04-11
JP2008510709A (ja) 2008-04-10
EP1793859A4 (de) 2008-02-13
HK1109054A1 (en) 2008-05-30
ATE526057T1 (de) 2011-10-15
RU2387455C2 (ru) 2010-04-27
CA2577777A1 (en) 2006-03-02
ES2322605T3 (es) 2009-06-23
RU2007110166A (ru) 2008-09-27
NO20071238L (no) 2007-05-14
AU2005277404A1 (en) 2006-03-02
EP2161032A2 (de) 2010-03-10
IL181286A0 (en) 2007-07-04
MX2007002134A (es) 2007-09-14
SI1793859T1 (sl) 2009-06-30

Similar Documents

Publication Publication Date Title
IL181286A0 (en) Methods of healing wounds by administering human il-18
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE60027415D1 (de) Zusammensetzung für die Verhinderung der Glattmuskelkrankheiten, die Ascorbat, Arginin und Magnesium enthält
EA200601777A1 (ru) Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
EP1543158A4 (de) Regulierte aptamer-therapeutika
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
DE602004010691D1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
ATE480243T1 (de) Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
ATE477820T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
DE502004011874D1 (de) Flupirtine-präparat zur behandlung von neurodegeneetes mellitus
VIVEK et al. Spectrum of Maxillary and Mandibular Fractures Among Patient Visiting Dental Hospital
DE602004009166D1 (de) Neue Analoga von Nitrobenzylthioinosin
DE50310383D1 (de) Humanes chondroosteomodulin (tig2), herstellung und verwendung zur behandlung oder diagnose von knochen- und knorpelerkrankungen, fettsucht sowie entzündlichen erkrankungen und hauterkrankungen
ATE447944T1 (de) Verwendung von formoterol in der prophylaktischen und/oder therapeutischen behandlung von muskelschwund und/oder kachexie-syndrom im zusammenhang mit katabolischen zuständen bei bestimmten krankheiten, wie z.b. krebs, aids, infektionen, diabetes und andere
DE60308862D1 (de) Verbindungen und zusammensetzungen zur behandlung von diabetes und erkrankungen, die mit diabetes in zusammenhang stehen
ATE468133T1 (de) Verwendung von g-csf als zusätzliche behandlung in die wiederherstellung von bindegewebe
Tanzella et al. Severe sepsis following staphylococcus hand infection in a 15-year-old boy Case report
ATE425765T1 (de) Verwendung von kollagen in kombination mit sauerstoff- und ozon-freisetzenden perfluorkohlenwasserstoffen zur herstellung eines medikaments zur behandlung von hautverletzungen
ATE406172T1 (de) Verwendung von löslichem cd14 zur behandlung von erkrankungen
FI20021180A0 (fi) Lääketieteellisen tutkimus- ja käsittelypöydän jatkesovitelma
PL1700597T3 (pl) Kompozycja farmaceutyczna do podawania na skórę, zawierająca łącznie ubidekarenon, despantenol oraz chlorheksydynę lub jej farmakologicznie dopuszczalną sól
WO2004069795A3 (en) Diagnosis and treatment of chronic tissue damage

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1793859

Country of ref document: EP